Crescent Biopharma (CBIO)
NASDAQ:CBIO
Want to see CBIO full AI Analyst Report?
CBIO Stock Chart & Stats
$21.28
--
Market closed
$21.28
--
Day’s Range― - ―
52-Week Range$8.72 - $27.57
Previous CloseN/A
VolumeN/A
Average Volume (3M)145.41K
Market Cap
$550.61M
Enterprise Value$362.99M
Total Cash (Recent Filing)$189.16M
Total Debt (Recent Filing)$1.54M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jul 30, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.91
Shares Outstanding27,571,936
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.61
Price to Sales (P/S)11.39
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue30.55
Enterprise Value/Gross Profit30.55
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$29.50Price Target Upside38.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.2
Revenue Forecast (FY)$1.93M
Bulls Say, Bears Say
Bulls Say
Clinical ProgressFirst patient dosing in the global ASCEND Phase 1/2 trial for CR-001 initiates human testing across multiple solid tumor types, creating an opportunity to generate early safety and activity data that could validate the program.
Differentiated Mechanism And Combination PotentialCR-001's engineered dual binding to PD-1 and VEGF concentrates activity in the tumor environment and may enhance responses when paired with antibody-drug conjugates, supporting a potential commercial advantage if clinical proof-of-concept is achieved.
Financing And RunwayA recent private placement supplies substantial financing that extends the company's operational runway through planned clinical milestones, lowering the immediate need for additional capital and supporting ongoing development.
Bears Say
Cash Burn And Net LossA large net loss driven by substantial research and licensing expenditures elevates cash burn risk and could require future fundraising that would dilute existing shareholders.
Operating Expense PressureA partner payment combined with stepped-up development spending has materially increased operating expenses, which can pressure near-term financial performance and investor sentiment.
Program Development RiskDiscontinuation of a similar PD-L1 by another company highlights the scientific and regulatory risk for related approaches, raising the possibility of clinical setbacks or the need to adjust development strategy.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $8.72 and its highest was $27.57 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $550.61M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Jul 30, 2026 which is in 74 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Apr 29, 2026. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.879 by $0.179.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate is -0.78.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 27,571,936 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.879. Following the earnings report the stock price went up 6.829%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (38.63% Upside)
$29.50 (38.63% Upside)
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 14.7%
Last 30 Days ▲ 14.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
-100.86%
Trailing 12-Months
Asset Growth
3223.16%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$29.50
▲(38.63% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―
Ownership Overview
12.51% Insiders
6.12% Mutual Funds
58.78% Other Institutional Investors
19.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---